Reflections on the early development of poxvirus vectors - PubMed (original) (raw)

Review

Reflections on the early development of poxvirus vectors

Bernard Moss. Vaccine. 2013.

Abstract

Poxvirus expression vectors were described in 1982 and quickly became widely used for vaccine development as well as research in numerous fields. Advantages of the vectors include simple construction, ability to accommodate large amounts of foreign DNA and high expression levels. Numerous poxvirus-based veterinary vaccines are currently in use and many others are in human clinical trials. The early reports of poxvirus vectors paved the way for and stimulated the development of other viral vectors and recombinant DNA vaccines.

Keywords: DNA cloning; Recombinant DNA; Recombinant vaccines; Vaccine vectors; Vaccinia virus.

Published by Elsevier Ltd.

PubMed Disclaimer

Conflict of interest statement

There is no apparent conflict of interest.

Figures

Fig. 1. Formation of vaccinia virus recombinants

The recombinant plasmid insertion vector contains a foreign gene preceded by a vaccinia virus promoter and flanked by vaccinia virus DNA that targets homologous recombination in cells infected with vaccinia virus. The recombinant virus can be identified or selected by a variety of methods.

Similar articles

• Vaccinia and other poxvirus expression vectors.
  Moss B. Moss B. Curr Opin Biotechnol. 1992 Oct;3(5):518-22. doi: 10.1016/0958-1669(92)90080-3. Curr Opin Biotechnol. 1992. PMID: 1368937 Review.
• Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
  Taylor J, Paoletti E. Taylor J, et al. Prog Vet Microbiol Immunol. 1988;4:197-217. Prog Vet Microbiol Immunol. 1988. PMID: 3078866 Review.
• Highly attenuated poxvirus vectors.
  Tartaglia J, Cox WI, Taylor J, Perkus M, Riviere M, Meignier B, Paoletti E. Tartaglia J, et al. AIDS Res Hum Retroviruses. 1992 Aug;8(8):1445-7. doi: 10.1089/aid.1992.8.1445. AIDS Res Hum Retroviruses. 1992. PMID: 1466978 No abstract available.
• Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates.
  Zhan Y, Deng Y, Huang B, Song Q, Wang W, Yang Y, Dai L, Wang W, Yan J, Gao GF, Tan W. Zhan Y, et al. Vaccine. 2019 Apr 3;37(15):2122-2130. doi: 10.1016/j.vaccine.2019.02.063. Epub 2019 Mar 6. Vaccine. 2019. PMID: 30851967
• Poxvirus-based vectors as vaccine candidates.
  Tartaglia J, Pincus S, Paoletti E. Tartaglia J, et al. Crit Rev Immunol. 1990;10(1):13-30. Crit Rev Immunol. 1990. PMID: 2407263 Review.

Cited by

• Rendezvous with Vaccinia Virus in the Post-smallpox Era: R&D Advances.
  Wang Y. Wang Y. Viruses. 2023 Aug 15;15(8):1742. doi: 10.3390/v15081742. Viruses. 2023. PMID: 37632084 Free PMC article. Review.
• A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model.
  Kreijtz JH, Wiersma LC, De Gruyter HL, Vogelzang-van Trierum SE, van Amerongen G, Stittelaar KJ, Fouchier RA, Osterhaus AD, Sutter G, Rimmelzwaan GF. Kreijtz JH, et al. J Infect Dis. 2015 Mar 1;211(5):791-800. doi: 10.1093/infdis/jiu528. Epub 2014 Sep 22. J Infect Dis. 2015. PMID: 25246535 Free PMC article.
• Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.
  Al Yaghchi C, Zhang Z, Alusi G, Lemoine NR, Wang Y. Al Yaghchi C, et al. Immunotherapy. 2015;7(12):1249-58. doi: 10.2217/imt.15.90. Epub 2015 Nov 23. Immunotherapy. 2015. PMID: 26595180 Free PMC article. Review.
• Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.
  Ramezanpour B, Pronker ES, Kreijtz JH, Osterhaus AD, Claassen E. Ramezanpour B, et al. Vaccine. 2015 Aug 20;33(35):4349-58. doi: 10.1016/j.vaccine.2015.04.086. Epub 2015 Jun 3. Vaccine. 2015. PMID: 26048779 Free PMC article.
• Advancements in the Growth and Construction of Recombinant Lumpy Skin Disease Virus (LSDV) for Use as a Vaccine Vector.
  van Diepen M, Chapman R, Douglass N, Whittle L, Chineka N, Galant S, Cotchobos C, Suzuki A, Williamson AL. van Diepen M, et al. Vaccines (Basel). 2021 Oct 4;9(10):1131. doi: 10.3390/vaccines9101131. Vaccines (Basel). 2021. PMID: 34696239 Free PMC article.

References

1. 1. Jackson DA, Symons RH, Berg P. Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc Natl Acad Sci USA. 1972;69:2904–9. - PMC - PubMed
2. 1. Wittek R, Barbosa E, Cooper JA, Garon CF, Chan H, Moss B. Inverted terminal repetition in vaccinia virus DNA encodes early mRNAs. Nature. 1980;285:21–5. - PubMed
3. 1. Wittek R, Cooper J, Barbosa E, Moss B. Expression of the vaccinia virus genome - analysis and mapping of mRNAs encoded within the inverted terminal repetition. Cell. 1980;21:487–93. - PubMed
4. 1. Baroudy BM, Venkatesan S, Moss B. Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain. Cell. 1982;28:315–24. - PubMed
5. 1. Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, Paoletti E. The complete DNA sequence of vaccinia virus. Virology. 1990;179:247–66. 517–63. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • H1 Connect
  • The Lens - Patent Citations Database
  • scite Smart Citations